Immunomedics Announces Conference Call and Webcast for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunomedics Announces Conference Call and Webcast for First Quarter Fiscal 2015 Financial Results

MORRIS PLAINS, N.J., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq: IMMU ) today announced that it will host a conference call and live audio webcast on Thursday, November 6, 2014 at 10:00 a.m. Eastern Time to discuss financial results for the first quarter of fiscal year 2015, and review key clinical developments and future planned activities.

To access the conference call, please dial (877) 303-2523 or (253) 237-1755 using the Conference ID 19069282. The conference call will be webcast via the Investors page on the Company's website at www.immunomedics.com . Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company's website for 30 days through December 5, 2014.

The Company will report financial results for the first quarter ended September 30, 2014 after the close of U.S. financial markets on Wednesday, November 5, 2014.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics' advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of nine clinical-stage product candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB), to whom the Company licensed epratuzumab for the treatment of all non-cancer indications worldwide. UCB expects Phase 3 data in systemic lupus erythematosus in the first half of 2015. Immunomedics is exploring epratuzumab in oncology in collaboration with independent cancer study groups. Immunomedics' most advanced candidate to which it retains worldwide rights for all indicationsis 90 Y-clivatuzumab tetraxetan. The Company initiated a Phase 3 registration trial in January 2014 in patients with advanced pancreatic cancer and expects topline data in mid-2016. Immunomedics' portfolio of wholly owned product candidates also includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics' most advanced ADCs are IMMU-132 and IMMU-130, which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development. These include bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK ® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 258 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. Immunomedics' strength in intellectual property has resulted in a top-8 ranking in the Biotechnology industry by the Patent Board for the 2014 fiscal year. For additional information on the Company, please visit its website at www.immunomedics.com . The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, risks associated with the outcome of pending litigation, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Grant Management (973) 605-8200, extension 123

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 56

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 63

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 94

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 234

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 11

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 53

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 253

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 208

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading

Top 5 Most Recently Viewed Articles

FlexShopper Partners with PayPossible to Enhance Payment Solutions

Updated Category News Views 152

FlexShopper Enhances Consumer Payment Solutions FlexShopper Inc., a leading name in lease-to-own (LTO) retail and payment solutions, is thrilled to share the news of its strategic partnership with PayPossible. This collaboration focuses on expanding flexible financing options for consumers through the integration of FlexShopper’s services into PayPossible’s renowned...

Continue Reading
SanDisk Set to Thrive Amid Rising AI Demand and Supply Gaps

Updated Category News Views 356

SanDisk Corporation and the Promise of AI Demand SanDisk Corporation (NASDAQ: SNDK) is experiencing a wave of investor optimism as shares surged recently. This positive sentiment primarily stems from the anticipated growth in the NAND flash memory market, driven by increasing demand from AI data centers and limited supply conditions. Market Dynamics and Future Performance...

Continue Reading
Exciting Preparations for FIFA World Cup 26 in Miami

Updated Category News Views 437

Countdown to FIFA World Cup 26 in Miami Greater Miami and Miami Beach: A Hub for Global Sports As we approach a thrilling year leading up to the FIFA World Cup 26™, anticipation builds across Greater Miami. Miami is set to solidify its status as a global sports capital, ready to host seven electrifying matches at the Hard Rock Stadium. The preparations are underway for...

Continue Reading
JKB and IFC's Bold Green Bond Move Spurs Finance

Updated Category News Views 22

Amman Sets the Stage for Green Finance Watch out, folks! Jordan Kuwait Bank (JKB), teaming up with the International Finance Corporation (IFC), is stirring the pot in Amman with its second Green Bond. This is no small fry—it’s a big-time financial ballet with a USD 100 million investment aimed squarely at reshaping the landscape of sustainable finance in Jordan....

Continue Reading
Discover Modern Living at Modera St. Paul in Dallas

Updated Category News Views 194

Modera St. Paul Opens Doors to New Residents Mill Creek Residential has recently welcomed its first residents to Modera St. Paul, a striking mixed-use community positioned in the heart of Dallas. This development adds a total of 333 homes alongside street-level retail space, creating a vibrant urban living experience. A Prime Location for Modern Living Situated at a key...

Continue Reading